Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.
Market Dynamics
Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.
Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.
Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC – an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.
Key features of the study:
- This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market
Detailed Segmentation:
- Global Viral Conjunctivitis Drugs Market, By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- Global Viral Conjunctivitis Drugs Market, By Virus Type:
- Adenovirus
- Enterovirus
- Others
- Global Viral Conjunctivitis Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Viral Conjunctivitis Drugs Market, By Region:
- North America
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Middle East
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Steroids
- Antibiotics
- By Virus Type:
- Adenovirus
- Enterovirus
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AbbVie Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox
- NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Okogen Inc.
“*” marked represents similar segmentation in other categories in the respective section.
